To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
Clinical trial NCT04675931 · COMPLETED
Trial details
- NCT number
- NCT04675931
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-07
- Primary completion
- 2025-07-24
- Enrollment
- 254
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.